Intellia Therapeutics (NTLA) Downgraded After Safety Concerns and Regulatory Delays Slow Gene-Editing Progress

Intellia Therapeutics, Inc. (NASDAQ:NTLA) ranks among the most oversold biotech stocks to invest in. On November 11, Jones Trading dropped Intellia Therapeutics, Inc. (NASDAQ:NTLA) from Buy to Hold. The downgrade came after Intellia announced on November 6, along with its third-quarter 2025 earnings, that a next-z treated patient who had originally met Hy’s Law criteria had died.

The downgrade also comes after Dr. Garcia and Jones Trading convened a key opinion leader call on November 5 to discuss the patient who met Hy’s Law criteria. The discussion took place prior to the patient’s death being announced the following day.

Baird, noting the FDA’s hold on the NTLA-2001 treatment as a major factor, also lowered its price target for the company’s shares to $9 while maintaining a Neutral rating. Given the competitive environment in the ATTR and HAE markets, the firm states that commercial adoption of Intellia’s programs may be difficult even if they gain regulatory approval.

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a biotech company at the forefront of CRISPR-Cas9 gene-editing technology, developing cutting-edge treatments for both in vivo and ex vivo applications. Its main initiative, NTLA-2001, aims to treat transthyretin amyloidosis, a disease that is currently incurable.

While we acknowledge the potential of NTLA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NTLA and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.